Home | Welcome to Contract Pharma   
Last Updated Saturday, May 18 2013
Print RSS Feed

Breaking News

Related Searches: Promotions & Moves •
Lilly

January 30, 2009
Enrique Conterno, currently senior vice president of health care professional markets for Lilly in the U.S., has been promoted to president, Lilly USA, LLC, effective immediately.  Read More »
Akorn

January 30, 2009
President and chief executive officer, Arthur Przybyl, is leaving Akorn, Inc.  Read More »
Eden Biodesign

January 30, 2009
Dr. Derek Ellison was appointed chief operating officer, Eden Biodesign.  Read More »
AstraZeneca 4Q08

January 29, 2009
Nexium sales were $1.3 billion in the quarter (+6%) but down 2% for the year to $5.2 billion. Losec/Prilosec sales were down 11% to $264 million in the quarter and down 14% to $1.1 billion for the year due to generic competition.  Read More »
Lilly 4Q08

January 29, 2009
Alimta, Byetta, Cialis, Cymbalta, Forteo, Strattera, Symbyax, Xigris and Yentreve sales collectively grew 10% to $1.9 billion and accounted for 37% of total sales, compared with 33% in 4Q07.  Read More »
SAFC Pharma Offers Assay Capabilities

January 29, 2009
SAFC Pharma began operations at its 7,000-sq.-ft. state-of-the-art lab complex in Carlsbad, CA.   Read More »
Argenta Discovery, Zafgen Enter Obesity Drug Pact

January 29, 2009
Argenta Discovery Ltd. and Zafgen, Inc. have entered a drug discovery collaboration to develop one of Zafgen’s therapeutics programs for obesity.  Read More »
Goodwin Manufactures Neogenix MAb for Trial

January 29, 2009
Goodwin Biotechnology, Inc. (GBI) completed the first phase of manufacturing of Neogenix Oncology’s monoclonal antibody, NPC-1C.  Read More »
Financial Report: Novartis 4Q

January 28, 2009
Pharmaceutical sales were $6.4 billion in the quarter (+5%) and $26.3 billion for the year (+10%), driven by growth in oncology, the cardiovascular portfolio and $2.9 billion of contributions from recently launched products including Aclasta/Reclast, Tekt  Read More »
Financial Report: Gilead 4Q

January 28, 2009
Product sales increased 35% to a record $1.4 billion in the quarter and for the year product sales were up 36% to $5.08 billion, driven primarily by Gilead’s antiviral franchise, and growth in sales of Atripla and Truvada.  Read More »
Almac Plans U.S. Expansion

January 28, 2009
Almac Clinical Services, a division of the Almac Group, plans further expansion with a new $110 million North American Headquarters in the U.S.  Read More »
Xcelience Expands GMP Manufacturing Capabilities

January 28, 2009
Xcelience expanded its GMP manufacturing capabilities with the purchase of three new pieces of equipment for API services for pharmaceutical companies.  Read More »
Financial Report: Bristol-Myers Squibb 4Q

January 27, 2009
Pharmaceutical sales were $4.5 billion in the quarter (+4%). U.S. pharmaceutical sales were up 13% to $2.8 billion, while international sales were down 9% to $1.7 billion, primarily due to an 8% unfavorable foreign exchange impact.  Read More »
Financial Report: PAREXEL 2Q

January 27, 2009
Consolidated service revenue for the quarter was $200.9 million in Clinical Research Services (CRS), $31.9 million in PAREXEL Consulting and Medical Communications Services (PCMS), and $43.0 million in Perceptive Informatics, Inc.  Read More »
Financial Report: Amgen 4Q

January 27, 2009
Product sales were up 2% to $3.7 billion in the quarter. Sales in the U.S. were up 1%, to $2.9 billion, while international sales increased 4% to $774 million.  Read More »

Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:

Follow Contract Pharma On
Please visit our sister sites: